2-amino-5-phosphonovalerate has been researched along with Dyskinesia, Medication-Induced in 2 studies
2-Amino-5-phosphonovalerate: The D-enantiomer is a potent and specific antagonist of NMDA glutamate receptors (RECEPTORS, N-METHYL-D-ASPARTATE). The L form is inactive at NMDA receptors but may affect the AP4 (2-amino-4-phosphonobutyrate; APB) excitatory amino acid receptors.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Morin, N | 1 |
| Morissette, M | 1 |
| Grégoire, L | 1 |
| Gomez-Mancilla, B | 1 |
| Gasparini, F | 1 |
| Di Paolo, T | 1 |
| Kannari, K | 1 |
| Markstein, R | 1 |
2 other studies available for 2-amino-5-phosphonovalerate and Dyskinesia, Medication-Induced
| Article | Year |
|---|---|
Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys.
Topics: 2-Amino-5-phosphonovalerate; Amino Acids; Animals; Basal Ganglia; Corpus Striatum; Dyskinesia, Drug- | 2013 |
Dopamine agonists potentiate antiakinetic effects of competitive NMDA-antagonists in monoamine-depleted mice.
Topics: 2-Amino-5-phosphonovalerate; alpha-Methyltyrosine; Animals; Binding, Competitive; Caudate Nucleus; D | 1991 |